Literature DB >> 11245477

Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.

T Michigami1, M Ihara-Watanabe, M Yamazaki, K Ozono.   

Abstract

Neuroblastoma originates from neural crest cells and is the most common extracranial solid tumor in childhood. Bone metastasis in neuroblastoma is an unfavorable prognostic factor even with intensive therapy. In the present study, we screened four cell lines of human neuroblastoma (NB-1, NB-16, NB-19, and NH-6) for tumorigenicity and metastatic capacity in nude mice and found that NB-19 cells caused osteolytic lesions after s.c. injection into mice. To detect micrometastases in the host tissue, we performed two kinds of PCR-based metastasis assays: (a) genomic PCR assay using the primers for human genome-specific Alu sequence; and (b) reverse transcription-nested PCR assay that detects the expression of tyrosine hydroxylase, a marker specific for neuroblastoma. The results of these PCR assays revealed the colonization of human neuroblastoma cells in the bone marrow of the mice that had received the s.c. injection of NB-19 cells. Because osteoclastic bone resorption has been reported to play important roles in osteolysis in some cancers such as breast cancer, we next examined the osteoclast (OC)-inducing activity of NB-19 cells using a coculture system in which NB-19 cells were cultured with murine bone marrow cells containing OC precursors and stromal cells. NB-19 cells induced tartrate-resistant acid phosphatase-positive multinucleated OC-like cells without requirement of 1,25-dihydroxyvitamin D3 or other osteoclastogenic stimulators. To investigate the factors involved in the osteoclastogenesis in the coculture of mouse marrow cells and NB-19 cells, we performed reverse transcription-PCR analysis and revealed the increased expression of receptor activator of nuclear factor kappaB ligand (RANKL) in the coculture compared with the culture of bone marrow cells alone. Interleukin-1alpha and cyclooxygenase-2 expression in the murine marrow cells was also increased in the presence of NB-19 cells. To further study the role of RANKL in the OC-like cell formation in the coculture of NB-19 cells and murine marrow cells, an expression vector encoding the active portion of the murine osteoprotegerin, which is the native inhibitor of RANKL action, was constructed and introduced into COS-7 cells. The conditioned media of the COS-7 cells transfected with the osteoprotegerin expression vector effectively blocked OC-like cell formation in the coculture of the bone marrow cells and NB-19 cells. These results suggested that in the bone microenvironment of NB-19-bearing mice, the stimulated expression of RANKL plays an important role in OC formation, leading to osteolytic bone metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245477

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

2.  Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis.

Authors:  Josephine H HaDuong; Laurence Blavier; Sanjeev K Baniwal; Baruch Frenkel; Jemily Malvar; Vasu Punj; Richard Sposto; Yves A DeClerck
Journal:  Int J Cancer       Date:  2015-02-21       Impact factor: 7.396

3.  Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

Authors:  Ming Ruan; Larry Pederson; Elizabeth W Bradley; Ana-Maria Bamberger; Merry Jo Oursler
Journal:  Endocrinology       Date:  2010-02-24       Impact factor: 4.736

4.  The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies.

Authors:  Giovanni Iolascon; Rosa Napolano; Margherita Gioia; Antimo Moretti; Ilaria Riccio; Francesca Gimigliano
Journal:  Clin Cases Miner Bone Metab       Date:  2013-01

5.  Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma.

Authors:  Reiko Ito; Hirofumi Nakayama; Kazuhiro Yoshida; Kazuya Kuraoka; Junichi Motoshita; Noriko Oda; Naohide Oue; Wataru Yasui
Journal:  Virchows Arch       Date:  2003-06-28       Impact factor: 4.064

6.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 7.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

8.  Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model.

Authors:  Joseph E Hartwich; W Shannon Orr; Catherine Y Ng; Yunyu Spence; Jillian M McLaughlin; Wayne L Furman; Lisa M McGregor; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2013-01       Impact factor: 2.545

9.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

10.  Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.

Authors:  T Ohshiba; C Miyaura; M Inada; A Ito
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.